Biogen Suffers Yet Another Setback as an Appeal for the Tecfidera Patent is Denied.
Summary: In a split decision, the U.S. Court of Appeals for the Federal Circuit affirmed a West Virginia federal court’s ruling that…
Summary: In a split decision, the U.S. Court of Appeals for the Federal Circuit affirmed a West Virginia federal court’s ruling that…
SYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s…
KEY POINTS: The U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Purified Cortrophin™ Gel…